Daily non-political popular news in brief.

New long-term data analyses for Bifeprunox show favorable effects vs. placebo

Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth, and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, today at the 2007 annual meeting of the American Psychiatric Association. New analyses of six-month data in stabilized adult patients with schizophrenia from a double-blind, placebo-controlled study demonstrated that bifeprunox maintained stability vs. placebo and displayed a favorable weight and lipid profile comparable with placebo.

Read more »

Keywords: long-term, data, analyses, bifeprunox, show, favorable, effects, placebo, long, term, analyse, effect

« Previous | Next »

Similar news on "New long-term data analyses for Bifeprunox show favorable effects vs. placebo":

1. EVEREST data on use of tolvaptan published in JAMA and featured at ACC
   03-27-2007 · EurekAlert!
   Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial EVEREST published in the March 28 issue of JAMA and presented at ACC.
   Similar news · Read more »
   
2. Safety analyses of clinical data for bifeprunox in patients with schizophrenia
   03-30-2007 · EurekAlert!
   Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Lundbeck A/S presented clinical study results on bifeprunox at an international medical congress this week. Safety analyses suggest bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, was associated with a favorable weight and lipid profile, comparable with placebo. In addition, increases in weight occurred in patients receiving active references versus placebo.
   Similar news · Read more »
   
3. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
   10-15-2007 · EurekAlert!
   REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis. According to a primary analysis of long-term extension data from the Active Ulcerative Colitis 1 and 2 trials, there is a 41 percent reduction in the incidence of colectomy, the surgical removal of the colon, in patients receiving REMICADE through 54 weeks, compared to those receiving placebo.
   Similar news · Read more »
   
4. ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan
   09-19-2007 · EurekAlert!
   A single dose of Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, resulted in favorable changes in hemodynamics associated with a significant increase in urine output in patients with advanced heart failure who participated in the international trial the EffeCt of ToLvaptan on HemodynamIc Parameters in Subjects with HEart failure, presented at the late breaking trials symposium of the Heart Failure Society of America's Annual Scientific Meeting.
   Similar news · Read more »
   
5. Longer term breast feeding protects mother from risk of developing rheumatoid arthritis
   06-15-2007 · EurekAlert!
   Breast feeding for a period of 13 months or more has been shown to reduce the mother's the risk of developing rheumatoid arthritis, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. In the study, the longer the breast feeding period, the lower the mother's risk of developing RA in later life. Comparable use of oral contraceptives or hormone replacement therapy did not show a significant effect on the risk of developing RA.
   Similar news · Read more »
   
6. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
   02-02-2008 · EurekAlert!
   One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
   Similar news · Read more »
   
7. IMRT versus 3D CRT for prostate cancer, new long-term data assesses side effects
   11-05-2006 · EurekAlert!
   New research findings show men have fewer long-term gastrointestinal side effects with intensity-modulated radiation therapy (IMRT) than with three-dimensional conformal radiation therapy (3D CRT) for prostate cancer treatment, despite the higher doses of radiation used in the IMRT group. These and other data, including long-term genitourinary side effects, were presented today.
   Similar news · Read more »
   
8. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
   10-23-2006 · EurekAlert!
   Patients with UC treated with Remicade® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase 3 clinical trial presented at the ACG meeting. Patients who responded and those who were in remission at one year had lower mean number of hospitalizations vs. non-responders through one year of treatment.
   Similar news · Read more »
   
9. Ski area affects mountain watershed, UVM study shows
   05-17-2007 · EurekAlert!
   In the first-ever study to document the effects of ski resort development on water flows and quality in the northeastern US, University of Vermont researchers studied side-by-side watersheds on Mount Mansfield. Their results show greater-than-expected water volume from the developed watershed, suggesting that models derived from timber extraction studies may underestimate the hydrologic effects of resort development. This study provides baseline data that may contribute to new stormwater management approaches in mountainside development.
   Similar news · Read more »
   
10. New ramelteon data presented at AARC
    12-03-2007 · EurekAlert!
    A study presented at the 53rd International Respiratory Congress of the American Association for Respiratory Care showed that ramelteon did not exacerbate respiratory depressant effects in patients (40 years and older) with moderate-to-severe chronic obstructive pulmonary disease, as measured by oxygenation or abnormal breathing events relative to placebo. Ramelteon 8mg is currently marketed as Rozerem.
    Similar news · Read more »